Pet Cloning Global Market Report 2024

The pet cloning market size has grown rapidly in recent years. It will grow from $3.25 billion in 2023 to $3.74 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to several factors, including an increase in the demand for pet preservation services, successful cloning initiatives in livestock, rising disposable income levels among pet owners, a trend towards humanizing pets, and an overall growth in the pet population.

The pet cloning market size is expected to see rapid growth in the next few years. It will grow to $6.66 billion in 2028 at a compound annual growth rate (CAGR) of 15.5%. The forecast period's growth can be attributed to personalized pet cloning services, a heightened awareness of cloning possibilities, a growing interest in genetic preservation, improved success rates in cloning techniques, and endorsements from celebrities. Major trends expected in this period include the growth of luxury pet services, the establishment of regulations specific to pet cloning, advancements in cloning accuracy, partnerships with veterinary clinics, and the integration of artificial intelligence into cloning processes.

Rising rates of pet ownership are expected to drive growth in the pet cloning market. Pet ownership involves caring for domesticated animals primarily for companionship rather than utility. Factors contributing to increased pet ownership include lifestyle changes, the humanization of pets, and higher disposable incomes. Pet cloning allows pet owners to preserve their beloved pets' genetic identity, offering continuity and comfort in the companionship experience. In October 2023, the American Pet Products Association reported that 86.9 million US households owned pets, accounting for 66% of households in 2022. Similarly, Animal Medicines Australia stated in November 2022 that 69% of Australian households owned pets. These rising ownership rates are fueling the growth of the pet cloning market.

Leading companies in the pet cloning market are prioritizing the development of advanced solutions such as oocyte-based reprogramming to improve cloning success rates and expand their market presence. Oocyte-based reprogramming involves resetting the genetic material of an egg cell to an embryonic state before introducing the DNA of the donor pet, facilitating successful cloning. For example, in May 2022, Embryll Life Sciences Inc. launched a cellular transplantation service that rejuvenates aging pets by transplanting young cells into them. This innovative process, utilizing oocyte-based reprogramming and animal cloning technology, produces cells matching the pet's DNA to avoid rejection or complications. Initially available for dogs, the service aims to prolong their lives and maintain youthful vitality.

In September 2022, Beijing Sinogene Biotechnology Co. Ltd. partnered with the Beijing Wildlife Park to collaborate on enhancing breeding for endangered animals and conserving biodiversity. Sinogene, a China-based pet cloning company specializing in animal cloning technology for consumers, intends to leverage its biotechnology capabilities for animal somatic cell preservation, genetic testing, and gene editing to support the conservation of rare and endangered wildlife in China. The partnership focuses on genetic and germplasm conservation, individual identification of wild animals, wildlife protection, population research, and public education about wildlife conservation. The Beijing Wildlife Park is dedicated to animal conservation in China.

Major companies operating in the pet cloning market are Trans Ova Genetics, Genetix Biotech Asia Pvt. Ltd., PPL Therapeutics, VectorBuilder Inc., Sinogene Pet Cloning, ViaGen LC, BioArts International, Boyalife Group, Cuddle clones, Gemini Genetics, PERPETUATE INC, Sooam Biotech, Oak Villlage Animal Hospital, Bella Vista Animal Hospital, BioVenic, Cyagra LLC, Embryll Life Sciences, My friend Again, Petslify, RNL Bio.

North America was the largest region in the pet cloning market in 2023. The regions covered in the pet cloning market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pet cloning market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pet cloning is a biotechnological procedure used to create a genetically identical replica of a pet animal. This is typically accomplished through somatic cell nuclear transfer (SCNT), where the nucleus of a donor cell is inserted into an egg cell that has had its nucleus removed. The resulting embryo is then transferred into a surrogate mother to develop into a cloned pet with the same genetic makeup as the original animal.

The primary types of pet cloning include deceased pet cloning and live pet cloning. Deceased pet cloning involves creating a genetic duplicate of a deceased pet using preserved cells or tissues to replicate its characteristics and traits. The technology involved in pet cloning includes somatic cell nuclear transfer, gene editing, and other techniques, serving various applications across species such as dogs, cats, horses, birds, reptiles, and more. The end users of pet cloning technology include pet owners, research institutes, breeding centers, zoos, and conservation programs.

The pet cloning research report is one of a series of new reports that provides pet cloning market statistics, including the pet cloning industry's global market size, regional shares, competitors with a pet cloning market share, detailed pet cloning market segments, market trends and opportunities, and any further data you may need to thrive in the pet cloning industry. This pet cloning market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pet cloning market consists of revenues earned by entities by providing services such as genetic counseling services, veterinary support for cloning procedures, DNA banking services, and post-cloning care and rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The pet cloning market also includes sales of cloning kits, genetic preservation solutions, pet cloning equipment sales, and customized cloning protocols. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.